Retinoblastoma and phosphate and tensin homolog tumor suppressors: Impact on ductal carcinoma in situ progression

Journal of the National Cancer Institute

Volumn 104, Issue 23, 2012, Pages 1825-1836

  Knudsen, Erik S ^a   Pajak, Thomas F ^d   Qeenan, Maria ^b   Mcclendon, A Kathleen ^b,c   Armon, Benjamin D ^b,c   Schwartz, Gordon F ^b,c   Witkiewicz, Agnieszka K ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RETINOBLASTOMA PROTEIN; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER INVASION; CANCER MODEL; CANCER RECURRENCE; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HAZARD RATIO; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; RISK ASSESSMENT; TUMOR SUPPRESSOR GENE;

ADULT; AGED; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PTEN PHOSPHOHYDROLASE; RETINAL NEOPLASMS; RETINOBLASTOMA; TUMOR SUPPRESSOR PROTEINS;

EID: 84870863931     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs446     Document Type: Article

References (45)

1. Virnig BA, Tuttle TM, Shamliyan T, Kane RL Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170-178.
2. Allegra CJ, Aberle DR, Ganschow P, et al National Institutes of Health State-of-the-Science Conference statement: diagnosis and management of ductal carcinoma in situ, September 22-24, 2009. J Natl Cancer Inst. 2010;102(3):161-169.
3. Erbas B, Provenzano E, Armes J., Gertig D. The natural history of ductal carcinoma in situ of the breast: a review. Breast Cancer Res Treat. 2006;97(2):135-144.
4. Kuerer HM, Albarracin CT, Yang W.T., et al Ductal carcinoma in situ: state of the science and roadmap to advance the field. J Clin Oncol. 2009;27(2):279-288.
5. Pinder SE, Duggan C, Ellis I.O., et al A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS trial. Br J Cancer. 2010;103(1):94-100.
6. Sanders ME, Schuyler PA, Dupont W.D., Page DL The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. ;103(12):2481-2484.
7. Hoque A, Sneige N, Sahin A.A., et al Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev. 2002;11(6):587-590.
8. Gauthier ML, Berman HK, Miller C, et al Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell. 2007;12(5):479-491.
9. Cornfield DB, Palazzo JP, Schwartz G.F., et al The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cancer. 2004;100(11):2317-2327.
10. Millar EK, Tran K, Marr P., Graham PH p27KIP-1, cyclin A and cyclin D1 protein expression in ductal carcinoma in situ of the breast: p27KIP-1 correlates with hormone receptor status but not with local recurrence. Pathol Int. 2007;57(4):183-189.
11. Nofech-Mozes S., Spayne J, Rakovitch E., et al Biological markers predictive of invasive recurrence in DCIS. Clin Med Oncol. 2008;2:7-18.
12. Oh YL, Choi JS, Song S.Y., et al Expression of p21Waf1, p27Kip1 and cyclin D1 proteins in breast ductal carcinoma in situ: relation with clinico-pathologic characteristics and with p53 expression and estrogen receptor status. Pathol Int. 2001;51(2):94-99.
13. Witkiewicz AK, Rivadeneira DB, Ertel A, et al Association of RB/ p16-pathway perturbations with DCIS recurrence dependence on tumor versus tissue microenvironment. Am J Pathol. 2011;179(3):1171-1178.
14. Oliveira AM, Ross JS, Fletcher JA Tumor suppressor genes in breast cancer: the gatekeepers and the caretakers. Am J Clin Pathol. 2005;124(Suppl):S16-S28.
15. Li J, Yen C, Liaw D., et al PTEN, a putative protein tyrosine phos-phatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943-1947.
16. Bose S, Crane A, Hibshoosh H., Mansukhani M, Sandweis L, Parsons R. Reduced expression of PTEN correlates with breast cancer progression. Hum Pathol. 2002;33(4):405-409.
17. Chow LM, Endersby R, Zhu X., et al Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell. 19(3):305-316.
18. Lester S. Perspectives on margins in DCIS: pathology. J Natl Compr Canc Netw. 2010;8(10):1219-1222.
19. Hammond ME, Hayes DF, Dowsett M, et al American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784-2795.
20. Witkiewicz AK, Rivadeneira DB, Ertel A, et al Association of RB/ p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol. 2011;179(3):1171-1178.
21. Sangale Z, Prass C, Carlson A., et al A robust immunohistochemical assay for detecting PTEN expression in human tumors. Appl Immunohistochem Mol Morphol. 2010;19(2):173-183.
22. Kerlikowske K, Molinaro AM, Gauthier M.L., et al Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst. 2011;102(9):627-637.
23. Rakovitch E, Nofech-Mozes S, Hanna W., et al HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2012;106(6):1160-1165.
24. Vitolo MI, Weiss MB, Szmacinski M, et al Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells. Cancer Res. 2009;69(21):8275-8283.
25. Arima Y, Hayashi H, Sasaki M., et al Induction of ZEB proteins by inactivation of RB protein is key determinant of mesenchymal phenotype of breast cancer. J Biol Chem. 2012;287(11):7896-7906.
26. Debnath J, Mills KR, Collins N.L., Reginato MJ, Muthuswamy SK, Brugge JS The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell. 2002;111(1):29-40.
27. Debnath J, Muthuswamy SK, Brugge JS Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods. 2003;30(3):256-268.
28. Hughes LL, Wang M, Page D.L., et al Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009;27(32):5319-5324.
29. Fisher B, Dignam J, Wolmark N., et al Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16(2):441-452.
30. Wapnir IL, Dignam JJ, Fisher B, et al Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2010;103(6):478-488.
31. Bijker N, Meijnen P, Peterse J.L., et al Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006;24(21):3381-3387.
32. Houghton J, George WD, Cuzick J, Duggan C., Fentiman IS, Spittle M. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003;362(9378):95-102.
33. Cuzick J, Sestak I, Pinder S.E., et al Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2010;12(1):21-29.
34. Claus EB, Chu P, Howe C.L., et al Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors. Exp Mol Pathol. 2001;70(3):303-316.
35. Vivanco I, Sawyers CL The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-501.
36. Depowski PL, Rosenthal SI, Ross JS Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol. 2001;14(7):672-676.
37. Perren A, Weng L P, Boag AH, et al Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999;155(4):1253-1260.
38. FitzGerald MG, Marsh DJ, Wahrer D, et al Germline mutations in PTEN are an infrequent cause of genetic predisposition to breast cancer. Oncogene. 1998;17(6):727-731.
39. Paramio JM, Navarro M, Segrelles C., Gomez-Casero E, Jorcano JL PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene. 1999;18(52):7462-7468.
40. Radu A, Neubauer V, Akagi T., Hanafusa H, Georgescu MM PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol. 2003;23(17):6139-6149.
41. Jiang Z, Deng T, Jones R., et al Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest. 2010;120(9):3296-3309.
42. Knudsen ES, Ertel A, Davicioni E., Kline J, Schwartz GF, Witkiewicz AK Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat. 2011;133(3):1009-1024.
43. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med. 2010;2(53):53ra75.
44. Knudsen ES, Knudsen KE Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer. 2008;8(9):714-724.
45. Knudsen ES, Wang JY Targeting the RB-pathway in cancer therapy. Clin Cancer Res. 2010;16(4):1094-1099.